The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cost implications of reactive versus prospective testing for dihydropyrimidine dehydrogenase (DPD) deficiency in patients with colorectal cancer.
Gul Ahmed
No relevant relationships to disclose
Jo O' Keeffe
No relevant relationships to disclose
Denise O Mullane
No relevant relationships to disclose
Alison Bransfield
No relevant relationships to disclose
Andrew Kenny
No relevant relationships to disclose
Aiman Mohd Nor
No relevant relationships to disclose
Nurul Asykin Hashim
No relevant relationships to disclose
Roisin O Sullivan
No relevant relationships to disclose
Kate Murphy
No relevant relationships to disclose
Raimundas Galiauskas
No relevant relationships to disclose
Brian Richard Bird
No relevant relationships to disclose
Conleth G. Murphy
No relevant relationships to disclose